OCI-Ly3 In Vitro High Content Screening (HCS) Assay

This assay is to provide OCI-Ly3-based In Vitro High Content Screening (HCS) Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

OCI-Ly3

Human

Human B-cell non-Hodgkin lymphoma cell line established in 1983 from the bone marrow sample of a 52-year-old man with B-cell non-Hodgkin lymphoma

Lymphoma

Oncology

In Vitro High Content Screening (HCS) Assay

HCS is one of the latest techniques used in cancer drug discovery programs. Unlike traditional HTS platforms, HCS provides more visual information about the experiment being conducted. HCS is a very powerful tool for multivariate and quantitative data analysis. Cellbased HCS systems have also gained much attention in biological research and cancer drug discovery programs.

High-throughput Screening, High Content Screening and Reporter Gene Assays